Сделать домашней|Добавить в избранное
 
 
baltic_kurs » Материалы за Июль 2005 года
Сортировать статьи по: дате | популярности | посещаемости | комментариям | алфавиту

Should prisoners get expensive hepatitis C drugs?

Автор: BlaxyDuarly от 25-07-2005, 12:07
Should prisoners get expensive hepatitis C drugs?

If used widely, a new generation of antiviral drugs has the potential to wipe out the deadly hepatitis C virus in the United States. But the high price of the drugs might prevent their use in prisons, which house as many as one-third of those who are infected. The drugs cost anywhere from about $65,000 to $170,000 for a single course of treatmentbetween three and nine times more than earlier treatments. Ronald Shansky, former medical director of the Illinois prison system and founder of the, described that price as "extortionarily high, criminal.

" Fair or not, the cost of the new drugs is likely to keep them out of reach for most infected prisoners. To put the price in perspective, the average annual cost for states to house an inmate is. The minimal cost of treating a single patien...

Hepatitis C Drug Development Catapults Onward

Автор: CymboroDargob от 24-07-2005, 19:42
Hepatitis C Drug Development Catapults Onward

The pace of, and progress in, hepatitis C virus (HCV) drug development are astonishing. In April 2011, proof-of-concept for safe, effective, peginterferon-free HCV treatment was announced. Since then, numerous trials have confirmed that hepatitis C virus is curable with direct-acting antivirals (DAAs), regardless of HCV treatment history, cirrhosis, or host genotype. Over the past 24 months, duration of treatment and assessment of posttreatment outcome have been dramatically abbreviated.

Old-school, 48-week regimens with SVR-24 are gone. Now, duration of treatment is usually 12 to 24 weeks, and SVR-12 is the endpoint that is commonly used as a surrogate for cure. Interim data are now available within a few months after trials start. This acceleration in, and rapid evolution of, HCV drug development has left some drugs behind: they are shackled to lumbering development programs, such as the strategy being used in many phase III trialsadding a DAA to 24 or 48 week...